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A
 
BSTRACT
 
By complete reading of the genome sequence, in the
near future we will be able to determine the role of
genomic DNA sequence variation among individuals,
such a single nucleotide polymorphism (SNP), in the
pathogenesis of diseases and responses to drugs.
Comprehension of the genome will also accelerate
understanding of the transcriptome, the whole tran-
scripts present in a cell. Messages induced by a
new therapy, such as an unexpected adverse effects,
will not be missed by using such a comprehensive
assay. Allergic diseases will be classified into subtypes
depending on the impaired or affected molecule.
Herein, I introduce our research strategy for genome-
wide analysis of SNP related to asthma, granted by the
Millennium Genome Project of the Japanese Govern-
ment, and review the recent results of transcriptome
analysis using microarray technology.
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I
 
NTRODUCTION
 
By using the genome sequence,
 
1–3
 
 it is expected that we
will resolve previously unanswered questions, such as
the probability of diseases. Now, we have obtained tools
for examining what the role of genomic DNA sequence
variations among individuals, such a single nucleotide
polymorphism (SNP),
 
4
 
 is in the pathogenesis of diseases
and responses to drugs. Comprehension of the genome
will also accelerate the understanding of the transcrip-
tome,
 
5
 
 the whole transcripts present in a cell, and the
proteome,
 
6
 
 the whole protein molecules present in a
cell that control cellular function (Fig. 1). Until recently,
considerable time and labor was required to measure
expression levels of genes, even for 100 transcripts.
However, by using the recently developed DNA chip
technology (i.e. cDNA microarrays
 
7
 
 and high-density
oligonucleotide probe arrays
 
8
 
), such systematic analysis
of transcriptomes has become practical. Even in the past
few years, such techniques have spread rapidly over
many research fields,
 
7–10
 
 including our own.
 
11–19
 
 Here,
I introduce our research strategy for the genome-wide
analysis of SNP related to asthma, granted by the
Millennium Genome Project of the Japanese Govern-
ment, and review the recent results of transcriptome
analysis using DNA chip technology.
 
S
 
TRATEGY
 
 
 
FOR
 
 
 
DISCOVERING
 
 
 
THE
 
 SNP 
 
RESPONSIBLE
 
 
 
FOR
 
 
 
ASTHMA
 
 
 
AND
 
 
 
ATOPY
 
In contrast with the term ‘mutation’, which exists in < 1%
of the whole population and often causes serious
hereditary diseases, SNP are present in > 1% of the
population and determine common individual vari-
ations, such as hair color.
 
4,20
 
 Single nucleotide poly-
morphisms are seen in 0.1% (approximately 3 million
pairs) of all genomic DNA sequences and are the
most common variation. Thus, by examining SNP, it is
expected that the probability of onset of common
diseases, such as hypertension
 
21
 
 or drug sensitiviy,
 
22
 
 can
be determined. Mutation due to single nucleotide
replacement in the case of an intractable disease and
the SNP responsible for drug sensitivity are often accom-
panied by complete loss of function of the protein. In
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contrast, the SNP responsible for common diseases are
accompanied by a mild reduction in the expression level
or function of gene products and should be affected by
environmental factors (Fig. 2). Of the various single
nucleotide replacements responsible for drug sensitivity,
in cases in which the gene product is unnecessary for
Fig. 1 Genome, transcrip-
tome, proteome. The gene is
transcribed and spliced into
mRNA (i.e. the transcript). The
mRNA is then translated into the
protein. The term ‘genome’
means all the genetic informa-
tion, including all genes. The
term ‘transcriptome’ means all
transcripts expressed in a cell
and the term ‘proteome’ means
all the functional elements in a
cell.
 
Fig. 2
 
Effect of single nucleotide replacement. If the protein completely loses its function, it often becomes life threatening. Life-
threatening nucleotide replacement inhibits the expansion of family members over the course of the long human history; thus, it
should be a rare mutation. If the loss-of-function protein did not affect the survival of our ancestors, the nucleotide replacement can
be a common single nucleotide polymorphism. With regard to polygenic common diseases, mild loss of function due to nucleotide
replacement may be involved.
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human survival, such as in the case of alcohol dehydro-
genase, the variation may be quite common.
 
23
 
 However,
when the gene product is essential for survival, the
functional loss should be very mild.
The term ‘atopy’ was coined in 1923 based on the
Greek word which means atypical, because it was
rare. The original concept of atopy has been explained
as an inherited predisposition to immediate-type hyper-
sensitivity reactions to common allergens. However,
atopy is currently considered to be acquired often as a
result of environmental influences because its prevalence
is increasing worldwide. When atopy is defined as one or
more positive results for specific IgE antibodies against
common allergens using 
 
in vitro
 
 or skin prick tests, the
prevalence of atopy is increasing in Japan.
 
24
 
 In a cohort
genomic study for atopy related genes, we found that the
prevalence of atopy was 92% in medical students raised
in large cities in Japan. In a private company, 88% of
workers born in 1971 or later were atopic, whereas only
44% workers born before 1971 were atopic.
 
25
 
 Children
raised on a farm tended to be less sensitized to common
allergens and have a lower prevalence of atopic dis-
eases.
 
26,27
 
 Although the exact mechanisms remain to be
determined, recent studies suggest that exposure to
endotoxin and other microbial components early in life
through contact with livestock may play an important
role in predisposing infants to a non-atopic constitu-
tion.
 
28,29
 
 Therefore, this difference in the prevalence of
atopy between the young and elderly may be related to
the rapid improvements in hygiene in the 1970s in
Japan.
Nevertheless, the definition of atopy is crucial in case-
control genomic studies of atopic diseases. It may be
necessary to define high atopy as serum IgE greater than
or equal to 10-fold 1 SD from normal plus multiple posi-
tive RAST scores.
 
30
 
 Bronchial asthma is often considered
to represent atopic disease, but is really a group of
diseases having similar symptoms with several different
pathological factors.
 
31
 
 For instance, childhood and adult
asthma have many different etiologies. There are so
many adult patients, but not childhood patients, whose
asthma pathology is based on IgE-independent inflam-
mation and inappropriate remodeling of airway tissue
following inflammation
 
32
 
 or aspirin sensitivity.
 
33
 
 In con-
trast, rhinovirus infections are common in asthma attacks
seen in pediatric patients.
 
34
 
 Therefore, to detect the SNP
on a molecule affecting a certain type of asthma, we
should specify what type of asthma by analyzing the clini-
cal information in detail.
 
P
 
HARMACOGENETICS
 
 
 
OF
 
 
 
ANTI
 
-
 
ASTHMA
 
 
 
DRUGS
 
Drug sensitivity based on genetic variance is considered
to be due to at least two different mechanisms. One is
the response to the drug and the other is drug meta-
bolism. Considering the drug response, a complete non-
responding gene for anti-asthma drugs has not been
identified and should not be common because the
majority of anti-asthma drugs are related to natural
hormones, such as glucocorticosteroids. Most studies
regarding glucocorticoid-resistance in asthma and other
allergic diseases explain glucocorticoid-resistance as
due to competitive actions by inflammatory cytokines.
That is, glucocorticoid-resistant patients usually have
severe inflammation followed by increased levels of the
transcriptional factor nuclear factor (NF)-
 
κ
 
B and the
glucocorticoid receptor 
 
β
 
, a decoy receptor, through
cytokine activation.
 
35
 
Regarding 
 
β
 
2
 
-adrenergic receptors, there is a func-
tional SNP affecting the affinity of these receptors for
agonists. When asthmatic patients who have an arginine/
arginine replacement in the 16th amino acid residue in
the 
 
β
 
2
 
-adrenergic receptor receive 
 
β
 
2
 
-adrenergic recep-
tor agonist therapy for 3 months, their lung function is
downregulated after withdrawal of the agonist.
 
36
 
 Although
the level of downregulation of 
 
β
 
2
 
-adrenergic receptors is
very low, it may sometimes cause asthma death.
In contrast with SNP related to the drug response,
many genetic variances are considered to be present in
metabolic enzymes, especially in the cytochrome P450
system.
 
37
 
 We have found that such SNP exist in cyto-
chrome P450 enzymes for glucocorticosteroid meta-
bolism.
 
38
 
 The SNP present in cytochrome P450 enzymes
may be related to the adverse reactions to drugs. It will be
important to determine whether such SNP are related to
the adverse reactions to glucocorticosteroids, such as
glaucoma.
 
A
 
PPLICATION
 
 
 
OF
 
 DNA 
 
CHIP
 
 
 
TECHNOLOGY
 
 
 
TO
 
 
 
THE
 
 
 
TRANSCRIPTOME
 
 
 
PROJECT
 
To understand the functional roles of the entire genome,
analysis of the proteome may be necessary. However, a
proteome assay is not yet practical, although recent
technological developments have made it possible to
measure a few hundred proteins at once. In fact, the
majority of proteins present in the proteome are still in
the ‘black box’ and their number is speculated to be
> 100 000, even if variable immunoglobulins and
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T cell receptors are not included. Thus, it remains labor-
intensive to analyze even 1% of proteins present in the
proteome. In contrast with proteomes, a transcriptome
assay has already become practical following rapid
developments in microarray technology. Now, there are
tools available for measuring the expression levels of
30 000 genes at once. It should be stressed that almost
all gene expression levels can be measured using recent
DNA chip technology, because the number of genes
present in the genome is estimated to be 30 000–
40 000. The ‘transcriptome’ refers to all, not simply
many, transcripts expressed in a cell. We will not miss
any previously unexpected adverse effects induced by a
new therapy by using such a comprehensive assay
(Fig. 3).
The transcriptome assay is useful for discovering
new diagnostic molecules. We have discovered 770 new
genes, which are expected as diagnostic tools or drug
targets, by using transcriptome assays in collaboration
with Genox Reseach Inc. (Kawasaki Laboratory, Teikyo
Univeristy Biotechnology Center, Kanagawa, Japan;
http://www.genox.co.jp/).14–17 The transcriptome assay
is also useful for detecting unexpected observations that
are often opposite or unrelated to previously published
information. We screened for cell-type specific gene
expression among the transcriptome in human mast cells
compared with other cell types. Of the transcripts for
expected mast cell-specific proteins, such as tryptase,
major basic protein (MBP), which had been thought to be
mostly eosinophil specific, was found to be expressed
abundantly by human mast cells.12 Mast cells obtained
from four different sources were found to have high
protein levels of MBP in their granules. Without using
comprehensive analysis such as DNA chip technology,
nobody would have found such an unexpected result.
Animal models of allergic inflammation have been
informative. The use of murine models of asthma has
increased mainly due to the ability to selectively knock out
genes that block specific pathways in the pathogenesis of
the disease. However, there is controversy over the rele-
vance of these murine models of asthma.39,40 It should be
noted that murine models of asthma lack the epithelial
injury due to the deposition of eosinophil granule com-
ponents, such as MBP.40
Thus, we used GeneChip (Affymetrix, Santa Clara,
CA, USA) to compare the transcriptomes of human and
mouse mast cells, because rodent mast cells are common
experimental tools but are somewhat different from their
Fig. 3 Impact of genome-wide
examination. Transcriptome as-
say may be useful for detecting
previously undiscovered side-
effects. The upper part of this
figure symbolizes the conven-
tional laboratory examination
and the lower part symbolizes
new laboratory examinations
using the transcriptome or pro-
teome. In the upper part of the
figure, the drug was judged to
be useful by conventional exam-
ination. However, you will find
adverse effects by screening all
elements, as can be seen in the
left-hand-most side tree.
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human counterparts in their responses to certain cytokines
and drugs. After stimulation via high-affinity IgE receptors
(Fc
 
ε
 
RI), the transcriptional levels of several CC chemo-
kines (i.e. I-309, macrophage inflammatory protein
(MIP)-1
 
α
 
 and MIP-1
 
β
 
) were found to be markedly
upregulated among the transcriptomes of both human
and mouse mast cells.
 
13
 
 These results suggests that
mast cells play a crucial role in recruitment of various
CC receptor (CCR)-expressing cells into the tissue in
an IgE-dependent manner and that Fc
 
ε
 
RI-mediated
induction of several CC chemokines is highly conserved
between humans and mice. In contrast, many other
genes are expressed in one of either type of mast cells
 
13
 
(i.e. the MBP transcript was expressed only by human
mast cells). Studies on the function of molecules highly
expressed only in mouse cells have to be interpreted
carefully with regard to their potential function in
humans. Interspecies comparison studies of whole
genome expression should be useful for the interpretation
of experimental data from animal models of human
pathogenesis.
 
C
 
ONCLUDING
 
 
 
COMMENTS
 
In the very near future, the probability of asthma, as well
as that of other allergic diseases, will be examined in
every hospital by screening all SNP and transcriptome
information related to the diseases. However, until now,
even the most-risky SNP combination related to asthma
has only a two- to threefold odds ratio with controls
 
41
 
and most SNP research papers deal only with statistical
probability. The effect of SNP on the protein structure or
expression levels has not usually been investigated.
Therefore, the SNP responsible for asthma and other
allergic diseases are sometimes different depending on
the publication and/or race or community studied.
Now, we need to resolve many problems before the
clinical application of such genomic information
regarding asthma and other allergic diseases. Among
these problems, the problem regarding the diagnosis of
asthma should be resolved urgently. Allergic diseases
will be classified into subtypes depending on the
affected molecule. For instance, the diagnosis will be
performed based on the affected molecules, such as
intercellular adhesion molecule-1-signaling pathway-
affected rhinovirus-induced asthma or a disintegrin and
metalloproteinase (ADAM)-33-affected glucocorticoid-
resistance asthma with hypertrophic airway smooth
muscle.
 
R
 
EFERENCES
 
1 Venter JC, Adams MD, Myers EW 
 
et al.
 
 The sequence of
the human genome. 
 
Science
 
 2001; 
 
291
 
: 1304–51.
2 International Human Genome Sequencing Consortium.
Initial sequencing and analysis of the human genome.
 
Nature
 
 2001; 
 
409
 
: 860–921.
3 Waterston RH, Lindblad-Toh K, Birney E 
 
et al.
 
 Initial
sequencing and comparative analysis of the mouse
genome. 
 
Nature
 
 2002; 
 
420
 
: 520–62.
4 Cargill M, Altshuler D, Ireland J 
 
et al.
 
 Characterization
of single-nucleotide polymorphisms in coding regions of
human genes. 
 
Nat. Genet.
 
 1999; 
 
22
 
: 231–8.
5 Velculescu VE, Madden SL, Zhang L 
 
et al.
 
 Analysis of
human transcriptomes. 
 
Nat. Genet.
 
 1999; 
 
23
 
: 387–3.
6 Apweiler R, Biswas M, Fleischmann W 
 
et al.
 
 Proteome
analysis database: Online application of InterPro and
CluSTr for the functional classification of proteins in
whole genomes. 
 
Nucleic Acids Res.
 
 2001; 
 
29
 
: 44–8.
7 Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM.
Expression profiling using cDNA microarrays. 
 
Nat. Genet.
 
1999; 
 
21: 10–14.
8 Lipshutz RJ, Fodor SPA, Gingeras TR, Lockhart DJ. High
density synthetic oligonucleotide arrays. Nat. Genet.
1999; 21: 20–4.
9 Fambrough D, McClure K, Kazlauskas A, Lander ES.
Diverse signaling pathways activated by growth
factor receptors induce broadly overlapping, rather
than independent, sets of genes. Cell 1999; 97:
727–41.
10 Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of
diffuse large B-cell lymphoma identified by gene expres-
sion profiling. Nature 2000; 403: 503–11.
11 Iida M, Matsumoto K, Tomita H et al. Selective down-
regulation of high affinity IgE receptor (Fc epsilon RI)
alpha-chain messenger RNA among transcriptome in
cord blood-derived versus adult peripheral blood-
derived cultured human mast cells. Blood 2001; 97:
1016–22.
12 Nakajima T, Matsumoto K, Suto H et al. Gene expression
screening of human mast cells and eosinophils using
high-density oligonucleotide probe arrays: Abundant
expression of major basic protein in mast cells. Blood
2001; 98: 1127–34.
13 Nakajima T, Inagaki N, Tanaka H et al. Marked increase
in CC chemokine gene expression in both human and
mouse mast cell transcriptomes following Fc epsilon
receptor I cross-linking: An interspecies comparison.
Blood 2002; 100: 3861–8.
14 Heishi M, Kagaya S, Katsunuma T et al. High-density
oligonucleotide array analysis of mRNA transcripts in
severe atopic dermatitis patients’ peripheral blood cells.
Int. Arch. Allergy Immunol. 2002; 129: 57–66.
15 Imai Y, Nakada A, Hashida R et al. Cloning and charac-
terization of the highly expressed ETEA gene from blood
cells of atopic dermatitis. Biochem. Biophys. Res.
Commun. 2002; 297: 1282–90.
70 H SAITO
16 Matsumoto Y, Oshida T, Obayashi I et al. Identification
of highly expressed genes in peripheral blood T cells from
patients with atopic dermatitis. Int. Arch. Allergy Immunol.
2002; 129: 327–40.
17 Ogawa K, Hashida R, Miyagawa M et al. Analysis of
gene expression in peripheral blood eosinophils from
patients with atopic dermatitis and in vitro cytokine-
stimulated blood eosinophils. Clin. Exp. Immunol. 2003
(in press).
18 Saito H, Nakajima T, Matsumoto K. Human mast cell
transcriptome project. Int. Arch. Allergy Immunol. 2001;
125: 1–8.
19 Matsumoto K, Saito H. Role of eosinophils in asthma:
Sarastro or the Queen of the Night? Int. Arch. Allergy
Immunol. 2001; 125: 290–6.
20 Bentley DR The Human Genome Project: An overview.
Med. Res. Rev. 2000; 20: 189–96.
21 Martin ER, Lai EH, Gilbert JR et al. SNPing away at
complex diseases: Analysis of single-nucleotide poly-
morphisms around APOE in Alzheimer disease. Am. J.
Hum. Genet. 2000; 67: 383–94.
22 Sesti F, Abbott GW, Wei J et al. A common polymorphism
associated with antibiotic-induced cardiac arrhythmia.
Proc. Natl Acad. Sci. USA 2000; 97: 10 613–18.
23 Koch HG, McClay J, Loh EW et al. Allele association
studies with SSR and SNP markers at known physical dis-
tances within a 1 Mb region embracing the ALDH2 locus in
the Japanese, demonstrates linkage disequilibrium extend-
ing up to 400 kb. Hum. Mol. Genet. 2000; 9: 2993–9.
24 Nakagomi T, Itaya H, Tominaga T, Yamaki M,
Hisamatsu S, Nakagomi O. Is atopy increasing? Lancet
1994; 343: 121–2.
25 Akasawa A, Matsumoto K, Tomikawa M et al. Prevalence
and gene expression screening of atopic subjects among
medical students in Japan. J. Allergy Clin. Immunol.
2001; 107 (Suppl.): S278 (Abstract).
26 von Mutius E. Environmental factors influencing the
development and progression of pediatric asthma.
J. Allergy Clin. Immunol. 2002; 109 (Suppl.): S525–32.
27 Braun Fahrländer C, Gassner M, Grize L et al. Prevalence
of hay fever and allergic sensitisation in farmer’s children
and their peers living in the same rural community.
SCARPOL team. Swiss Study on Childhood Allergy and
Respiratory Symptoms with Respect to Air Pollution. Clin.
Exp. Allergy 1999; 32: 28–34.
28 Gereda JE, Leung DYM, Thatayatikom A et al. Relation
between housedust endotoxin exposure, type 1 T cell
development, and allergen sensitisation in infants at high
risk of asthma. Lancet 2000; 32: 1680–3.
29 Matricardi PM, Rosmini F, Rapicetta M, Gasbarrini G,
Stroffolini T. Atopy, hygiene, and anthroposophic lifestyle.
San Marino Study Group. Lancet 1999; 354: 430.
30 Zimmerman B, Forsyth S, Gold M. Highly atopic children
formation of IgE antibody to food protein, especially
peanut. J. Allergy Clin. Immunol. 1989; 83: 764–70.
31 Pride NB. Asthma. Definition and clinical spectrum.
Br. Med. Bull. 1992; 48: 1–9.
32 Jeffery PK. Remodeling in asthma and chronic obstructive
lung disease. Am. J. Respir. Crit. Care Med. 2001; 164
(Suppl.): S28–38.
33 Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH.
Leukotriene-receptor expression on nasal mucosal inflam-
matory cells in aspirin-sensitive rhinosinusitis. N. Engl. J.
Med. 2002; 347: 1493–9.
34 Gern JE, Busse WW. Relationship of viral infections to
wheezing illnesses and asthma. Nat. Rev. Immunol.
2002; 2: 132–9.
35 Leung DYM, Bloom JW. Update on glucocorticoid action
and resistance. J. Allergy Clin. Immunol. 2003; 97:
1–20.
36 Moore PE, Laporte JD, Abraham JH et al. Polymorphism
of the β2-adrenergic receptor gene and desensitization in
human airway smooth muscle. Am. J. Respir. Crit. Care
Med. 2000; 162: 2117–24.
37 Buters JT, Sakai S, Richter T et al. Cytochrome
P450   CYP1B1 determines susceptibility to 7,12-
dimethylbenz[a]anthracene-induced lymphomas. Proc.
Natl Acad. Sci. USA 1999; 96: 1977–82.
38 Koyano S, Kurose K, Ozawa S et al. Eleven novel single
nucleotide polymorphisms in the NR1I2 (PXR) gene, four
of which induce non-synonymous amino acid alterations.
Drug Metab. Pharmacokin. 2003 (in press).
39 Gelfand EW. Mice are a good model of human airway
disease. Am. J. Respir. Crit. Care Med. 2002; 166: 5–6.
40 Persson CGA. Mice are not a good model of human
airway disease. Am. J. Respir. Crit. Care Med. 2002;
166: 6–7.
41 Van Eerdewegh P, Little RD, Dupuis J et al. Association of
the ADAM33 gene with asthma and bronchial hyper-
responsiveness. Nature 2002; 418: 426–30.
